Cargando…
Acceptability of the reusable SurePal™ self-injection device for Omnitrope(®) among pediatric patients: results from a questionnaire-based, cross-sectional, multicenter observational study
BACKGROUND: SurePal™ is a reusable self-injection system that has been developed to support daily administration of Omnitrope(®) (Sandoz, Kundl, Austria). A questionnaire-based cross-sectional survey was conducted to evaluate acceptability of, and preference for, SurePal™ in pediatric patients who w...
Autores principales: | Partsch, Carl-Joachim, Schnabel, Dirk, Ehtisham, Sarah, Johnstone, Helen C, Zabransky, Markus, Kiess, Wieland |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4578482/ https://www.ncbi.nlm.nih.gov/pubmed/26405430 http://dx.doi.org/10.2147/MDER.S93209 |
Ejemplares similares
-
Acceptance of a reusable self-injection device for recombinant human growth hormone: final data from a questionnaire-based, cross-sectional, international, multicenter, observational study in pediatric patients
por: Schnabel, Dirk, et al.
Publicado: (2016) -
The effect of surgery report cards on improving radical prostatectomy quality: the SuRep study protocol
por: Breau, R. H., et al.
Publicado: (2018) -
SAT-437 The Patro Adults Study of Omnitrope® for the Treatment of Adult Patients with Growth Hormone Deficiency: Latest Safety Outcomes Including Diabetes Risk
por: Beck-Peccoz, Paolo, et al.
Publicado: (2019) -
Malignancy risk in adults with growth hormone deficiency undergoing long-term treatment with biosimilar somatropin (Omnitrope(®)): data from the PATRO Adults study
por: Beck-Peccoz, Paolo, et al.
Publicado: (2020) -
Safety and effectiveness of Omnitrope(®) (somatropin) in PATRO Children: a multi-center, post-marketing surveillance study comparison of US and international cohort data
por: Backeljauw, Philippe, et al.
Publicado: (2022)